ChemInform Abstract: Synthesis and Antiviral Activity of N-4′-Dihydropyridinyl and Dihydroquinolinylcarbonyl-2-hydroxymethyl-5-(cytosin-1′-yl)-1,3- oxathiolane Derivatives (V) Against Human Immunodeficiency Virus and Duck Hepatitis B Virus.

ChemInform ◽  
2010 ◽  
Vol 27 (46) ◽  
pp. no-no
Author(s):  
M. CAMPLO ◽  
A. S. CHARVET-FAURY ◽  
C. BOREL ◽  
F. TURIN ◽  
O. HANTZ ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
Duck Hepatitis B Virus ◽  
Duck Hepatitis ◽  
B Virus ◽  
Immunodeficiency Virus

scholarly journals Nucleic Acid Polymers Inhibit Duck Hepatitis B Virus InfectionIn Vitro

2013 ◽  
Vol 57 (11) ◽  
pp. 5291-5298 ◽  
Author(s):  
Faseeha Noordeen ◽  
Andrew Vaillant ◽  
Allison R. Jilbert
Keyword(s):  
Hepatitis B Virus ◽  
Nucleic Acid ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
Type I ◽  
Diverse Range ◽  
Duck Hepatitis B Virus ◽  
Duck Hepatitis ◽  
B Virus

ABSTRACTNucleic acid polymers (NAPs) utilize the sequence-independent properties of phosphorothioate oligonucleotides (PS-ONs) to target protein interactions involved in viral replication. NAPs are broadly active against a diverse range of enveloped viruses that use type I entry mechanisms. The antiviral activity of NAPs against hepatitis B virus (HBV) infection was assessedin vitroin duck hepatitis B virus (DHBV)-infected primary duck hepatocytes (PDH). NAPs efficiently entered PDH in the absence of any transfection agent and displayed antiviral activity at concentrations of 0.01 to 10 μM, measured by their ability to prevent the intracellular accumulation of DHBV surface antigen, which was independent of their nucleotide sequence and was specifically dependent on phosphorothioation. Higher levels of antiviral activity were observed with NAPs 40 nucleotides in length or longer. The fully degenerate NAP (REP 2006) was active during DHBV infection or when added 12 h after infection. In contrast, an acidic-pH-sensitive NAP (REP 2031) that was broadly active against other viruses displayed antiviral activity when present during DHBV infection but no activity when added 12 h after infection, suggesting that NAPs exert their postentry effect in an acidic environment unique to DHBV infection. Both REP 2006 and REP 2031 displayed negligible cytotoxicity in PDH at concentrations of up to 10 μM, as assessed using an XTT [2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] cytotoxicity assay. The antiviral activity of NAPs against DHBVin vitrowas strictly dependent on their amphipathic character, suggesting that NAPs interact with amphipathic target(s) that are important for DHBV entry and postentry mechanisms required for infection.

scholarly journals Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles.

1997 ◽  
Vol 41 (11) ◽  
pp. 2579-2581 ◽  
Author(s):  
O Hantz ◽  
C Borel ◽  
C Trabaud ◽  
F Zoulim ◽  
J Dessolin ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Activity ◽  
Selective Inhibition ◽  
Early Step ◽  
Duck Hepatitis B Virus ◽  
New Class ◽  
Duck Hepatitis ◽  
Significant Toxicity ◽  
B Virus

The antiviral activity of a new class of N,N,N',N",NA'''-pentakis (omega-aminoalkyl) tetraazamacrocycles was evaluated in primary duck hepatocyte cultures infected with the duck hepatitis B virus (DHBV). Three of the four tested compounds were able to selectively inhibit DHBV replication by acting at an early step of the hepadnavirus infection but were associated with significant toxicity.

Integrated structures of duck hepatitis B virus DNA in hepatocellular carcinoma.

1988 ◽  
Vol 62 (3) ◽  
pp. 861-865 ◽  
Author(s):  
F Imazeki ◽  
K Yaginuma ◽  
M Omata ◽  
K Okuda ◽  
M Kobayashi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Duck Hepatitis B Virus ◽  
Hepatitis B Virus Dna ◽  
Duck Hepatitis ◽  
B Virus ◽  
Integrated Structures

scholarly journals Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus

2020 ◽  
pp. 1-10
Author(s):  
Axel Pruß ◽  
Akila Chandrasekar ◽  
Jacinto Sánchez-Ibáñez ◽  
Sophie Lucas-Samuel ◽  
Ulrich Kalus ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Tissue Donors ◽  
Occult Hbv Infection ◽  
Occult Hbv ◽  
B Virus ◽  
Immunodeficiency Virus

<b><i>Background:</i></b> Although transmission of pathogenic viruses through human tissue grafts is rare, it is still one of the most serious dreaded risks of transplantation. Therefore, in addition to the detailed medical and social history, a comprehensive serologic and molecular screening of the tissue donors for relevant viral markers for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) is necessary. In the case of reactive results in particular, clear decisions regarding follow-up testing and the criteria for tissue release must be made. <b><i>Methods:</i></b> Based on the clinical relevance of the specific virus markers, the sensitivity of the serological and molecular biological methods used and the application of inactivation methods, algorithms for tissue release are suggested. <b><i>Results:</i></b> Compliance with the preanalytical requirements and assessment of a possible hemodilution are mandatory requirements before testing the blood samples. While HIV testing follows defined algorithms, the procedures for HBV and HCV diagnostics are under discussion. Screening and decisions for HBV are often not as simple, e.g., due to cases of occult HBV infection, false-positive anti-HBc results, or early window period positive HBV NAT results. In the case of HCV diagnostics, modern therapies with direct-acting antivirals, which are often associated with successful treatment of the infection, should be included in the decision. <b><i>Conclusion:</i></b> In HBV and HCV testing, a high-sensitivity virus genome test should play a central role in diagnostics, especially in the case of equivocal serology, and it should be the basis for the decision to release the tissue. The proposed test algorithms and decisions are also based on current European recommendations and standards for safety and quality assurance in tissue and cell banking.

Sign in / Sign up

Export Citation Format

Share Document